Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model
Z. Nikolova et al., Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model, TRANSPLANT, 72(1), 2001, pp. 168-171
Background. FTY720 lowers the peripheral lymphocyte count (PLC) by accelera
ting the migration of circulating lymphocytes to secondary lymphoid organs.
We investigated the efficacy of combined FTY720+cyclosporine (CsA) treatme
nt versus monotherapy on prolonging graft survival and on lowering the PLC.
Methods. BALB/c hearts were heterotopically grafted in C3H mice. FTY720 was
administered alone or in combination with CsA PLC and body weight were det
ermined on day 7, day 28, or the day of rejection.
Results. Combining FTY720 with CsA prolonged, dose-dependently and signific
antly, the allograft survival. FTY720, but not CsA, lowered the PLC dose-de
pendently. The granulocyte count was not reduced in any group. FTY720 conce
ntrations were not influenced by the CsA co-administration,
Conclusions. Combined FTY720 and CsA treatment was well tolerated, promoted
graft survival, and suppressed the inflammatory allo-response, The PLC low
ering correlated well with the antirejection effects in the two-drug regime
ns, suggesting that the PLC might guide FTY720 therapy at low doses.